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Introduction
Chronic kidney disease (CKD) is a widespread condition affecting over 30 million people in the United 
States and about 10% of  the population worldwide (1). The progression of  this disease results in kidney fail-
ure, also known as end-stage renal disease (ESRD). ESRD causes nearly a million deaths each year globally, 
and over 2 million people are currently receiving treatment. However, it is estimated that this is only a frac-
tion of  the people in need of  treatment because of  the expense and limited availability of  currently available 
therapies (chronic dialysis sessions or organ transplant), leading to over 1 million deaths each year (2).
Fibrosis is the final common pathway and histological manifestation of  highly prevalent clinical con-
ditions that lead to CKD, such as hypertension, nephroangiosclerosis, and diabetic nephropathy (DN). 
It is characterized by the accumulation of  collagen, activated myofibroblasts, and inflammatory cells, as 
well as cell death, epithelial cell dedifferentiation, and loss of  vascular supply in the kidney (3, 4). Renal 
tubule cells have high baseline metabolic needs and rely mostly on fatty acids as their primary fuel source 
to generate energy via mitochondrial oxidative phosphorylation (5). They have high levels of  peroxisomal 
proliferator–activated receptor-α (PPARα) and PPARγ coactivator-1α (PGC-1α) and a dense mitochondrial 
network to support their metabolic and functional needs (6).
Previous work has reported the important links between cellular bioenergetics and the development 
of chronic kidney disease, highlighting the potential for targeting metabolic functions to regulate 
disease progression. More recently, it has been shown that alterations in fatty acid oxidation (FAO) 
can have an important impact on the progression of kidney disease. In this work, we demonstrate 
that loss of miR-33, an important regulator of lipid metabolism, can partially prevent the repression 
of FAO in fibrotic kidneys and reduce lipid accumulation. These changes were associated with a 
dramatic reduction in the extent of fibrosis induced in 2 mouse models of kidney disease. These 
effects were not related to changes in circulating leukocytes because bone marrow transplants 
from miR-33–deficient animals did not have a similar impact on disease progression. Most 
important, targeted delivery of miR-33 peptide nucleic acid inhibitors to the kidney and other 
acidic microenvironments was accomplished using pH low insertion peptides as a carrier. This was 
effective at both increasing the expression of factors involved in FAO and reducing the development 
of fibrosis. Together, these findings suggest that miR-33 may be an attractive therapeutic target for 
the treatment of chronic kidney disease.
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Alterations in metabolic function are one of  the biggest risk factors for CKD. Elevated blood 
glucose levels are known to promote kidney dysfunction, and nearly one-third of  patients with dia-
betes develop nephropathy (7). More recently, abnormal renal lipid accumulation has been linked 
to the development of  CKD and renal fibrosis (8). This has led to the prevailing concept that tubu-
lo-interstitial fibrosis can be mediated or perpetuated by metabolic alterations, whereby reduced fatty 
acid oxidation (FAO) plays a central role in promoting and prolonging fibrotic responses (9–13). The 
use of  different models of  chronic kidney injury leading to renal fibrosis, including unilateral ureter-
al obstruction (UUO), folic acid–induced nephropathy (FAN), ischemia/reperfusion, or genetically 
modified models, has allowed researchers to establish that this reduction is associated with decreased 
expression of  numerous FAO-related genes in renal tubular epithelial cells (TECs). Facing those met-
abolic constraints, TECs that survive injury respond by rearranging their cytoskeleton and acquiring a 
less differentiated, mesenchymal phenotype (14).
Carnitine palmitoyltransferase 1a (CPT1a) is a mitochondrial enzyme central to the regulation of  
FAO, through its role in the transport of  long chain fatty acids from the cytoplasm into the mitochondria. 
Reduction in the levels of  this enzyme has been linked to an activation of  the TGF-β axis in the context of  
inflammatory response, leading to fibrogenesis through the inhibition of  PPARα-dependent downstream 
signaling (11). However, therapies based on the inhibition of  TGF-β signaling have not yet been proved 
valuable in human disease. Likewise, the use of  fibrates as agonists of  the PPARα family of  receptors has 
been curtailed in the clinic because of  side effects involving renal function (15). Thus, it is important to 
investigate new strategies that may provide a basis for therapeutic targets.
miRNAs are noncoding RNAs whose importance in pathophysiology has steadily grown over the 
past decade. The ability of  a single miRNA to inhibit a large number of  mRNA targets can allow miR-
NAs to promote more robust responses by targeting multiple genes in the same or related pathways or to 
elicit a broader cellular response by targeting genes in pathways that are generally not related. Although 
this provides miRNAs the ability to regulate a wide variety of  complex cellular responses, it also makes 
it difficult to determine the specific mechanisms by which miRNAs mediate their effects. Recently, our 
group was able to demonstrate that disruption of  an individual miRNA/target interaction was sufficient 
to mimic many of  the effects of  miRNA deficiency in vivo. Although this was the first work demonstrat-
ing the capacity of  an individual miRNA/target interaction to mediate complex physiological pheno-
types, the more moderate phenotype suggests other targets may also have been involved (16). Indeed, in 
most cases multiple mRNA targets are likely involved in mediating the effects of  an miRNA, and to add 
a new level of  complexity, the effects of  a given miRNA can vary dramatically among tissues, cell types, 
and physiological states because of  differences in expression and target availability.
Several miRNAs have been related to the regulation of  renal responses during fibrosis (17–19). Previ-
ous reports demonstrated that downregulation of  miR-214 and miR-21, which have increased expression 
in models of  renal damage and are implicated in human renal pathology, is protective against renal fibrosis 
(20–22). Alternatively, miR-29 expression is suppressed by TGF-β, promoting collagen expression and renal 
fibrosis (23). However, the role of  miRNAs in the regulation of  renal fibrosis is still largely unexplored, and 
recent work demonstrating the ability of  miRNAs to regulate cellular bioenergetics suggests that these 
novel regulators could constitute a pathogenic link between metabolism and fibrogenesis. We hypothesized 
that miR-33, a major regulator of  lipid metabolism, could represent an attractive candidate in this setting.
The miR-33 family of  miRNAs are encoded within the sterol regulatory binding protein (SREBP) 
genes. SREBP1 and SREBP2 are transcription factors responsible for the regulation of  fatty acid and 
cholesterol biosynthesis. miR-33a and miR-33b are cotranscribed along with their host genes and work 
in a concerted manner by targeting genes involved in cholesterol efflux (ABCA1, ABCG1) (24, 25) and 
FAO (CPT1a, CROT, HADHB) (26, 27). miR-33 is highly expressed in human and mouse kidneys (24, 
25). Recent work has shown that miR-33 expression is increased in the serum of  patients with diabetes 
and even further elevated in patients with DN. Similarly, rodents with DN had higher levels of  miR-33 
both in blood and in renal tissue (28). In this work, we utilize miR-33–knockout mice (miR-33–/–) to inves-
tigate how genetic loss of  miR-33 affects the development of  kidney fibrosis. Our results indicate that 
miR-33–deficient animals are protected from kidney fibrosis. This is likely due at least in part to reduced 
renal lipid accumulation and increased expression of  miR-33 target genes involved in FAO. We further 
demonstrate that selective delivery of  miR-33 peptide nucleic acid (PNA) inhibitors to the kidney, and 
other acidic environments, using a pH low insertion peptide (pHLIP) carrier increased the expression of  
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enzymes involved in FAO. Similar to what we observed in miR-33–/– mice, this treatment was effective in 
reducing kidney fibrosis and inducing factors related to kidney damage. This approach may represent a 
novel therapeutic avenue for the treatment of  kidney disease.
Results
Loss of  miR-33 protects mice against kidney fibrosis. We sought to determine whether miR-33 may play a direct 
role in promoting the development of  kidney dysfunction using 2 common models of  kidney fibrosis, FAN 
and UUO. Seven days after intraperitoneal (i.p.) injection of  folic acid (Figure 1A), mice deficient in miR-33 
showed a dramatic reduction in the development of  kidney fibrosis compared with WT mice. Histological 
analysis revealed that miR-33–/– mice had reduced accumulation of  collagen as visualized by Sirius red stain-
ing (Figure 1B). The induction of  fibrosis-associated markers (α–smooth muscle actin [α-SMA], fibronectin 
[FN1], and collagen) in response to folic acid was also reduced in miR-33–/– mice at both the mRNA (Figure 
1C) and protein levels (Figure 1D). Furthermore, common parameters indicative of  kidney function, blood 
urea nitrogen (BUN) and creatinine, were increased in animals injected with folic acid while this response 
was blunted in miR-33–/– animals (Figure 1E). Notably, miR-33 and Srebp2 expression were not found to be 
significantly altered in response to FAN (Supplemental Figure 1, A and B; supplemental material available 
online with this article; https://doi.org/10.1172/jci.insight.131102DS1), suggesting that suppression of  
basal miR-33 expression was sufficient to protect against folic acid–induced kidney fibrosis.
Similar results were obtained in miR-33–/– and control animals using an independent model of  renal dys-
function, UUO surgery (Figure 2A). In this model UUO surgery is performed only in 1 kidney, leaving the 
contralateral kidney as a nonfibrotic control. Similar to the findings observed in the FAN model, expression 
Figure 1. Loss of miR-33 is protective against folic acid–induced renal fibrosis. (A) Renal fibrosis in WT and miR-33–/– mice was induced by i.p. injection 
of folic acid (FA) (250 mg/kg body weight) (B). Representative microphotographs from 1 mouse per group and quantification (right) of Picrosirius red 
staining of kidneys from WT and miR-33–/– mice under control (CT) conditions or following treatment with FA, indicating collagen deposition/accumulation 
(n = 3–5). (C) Quantitative reverse transcription PCR (qRT-PCR) analysis of the expression of fibrosis-associated genes ASMA, FN1, and COL1A1 in kidneys 
from WT and miR-33–/– mice under CT conditions or following treatment with FA (n = 5–6). (D) Representative images and quantification of Western blot 
analysis of protein expression of fibrosis-associated genes: α-SMA, FN1, and COLIII in kidneys from WT and miR-33–/– mice under CT conditions (top) or 
following treatment with FA (bottom). Relative protein levels were determined by band densitometry and are expressed in AU after correction for loading 
CT GAPDH (n = 5). (E) Quantification of levels of BUN (left) and creatinine (right) in plasma samples of WT and miR-33–/– mice under CT conditions or 
following treatment with FA (n = 5–7). All statistical significance was determined using nonparametric 2-tailed Mann-Whitney U test. Data represent the 
mean ± SEM and *P < 0.05 comparing miR-33–/– with WT mice under the same conditions. Scale bar: 20 μm.
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of  miR-33 and Srebp2 was unaffected by UUO surgical procedure (Supplemental Figure 1, C and D). How-
ever, induction of  fibrosis-associated genes was significantly reduced in miR-33–/– mice at both the mRNA 
(Figure 2B) and protein levels compared with WT mice (Figure 2C). Despite the presence of  a functional 
contralateral kidney, we also observed a trend toward decreased plasma BUN in miR-33–/– mice both 3 and 
10 days after UUO surgery, along with a significant decrease in creatinine after 3 days of  UUO (Figure 2D). 
Together these findings demonstrate that loss of  miR-33 is protective against kidney fibrosis in rodents.
Protection against kidney fibrosis in miR-33–/– mice is not due to changes in circulating macrophages or other hematopoi-
etic cells. Similar to what we observed with fibrotic genes, the induction of mediators of inflammatory response 
in animals treated with folic acid was blunted in kidneys from miR-33–/– animals, compared with WT controls 
(Figure 3A). Because miR-33 has been shown to play an important role in the development of other chronic 
inflammatory conditions, such as atherosclerosis, and to regulate macrophage polarization (29), we investigated 
whether the reduced inflammation and fibrosis of miR-33–/– mice was due to effects on macrophages or other 
Figure 2. Renal fibrosis is reduced in miR-33–/– mice following UUO. (A) Kidney fibrosis was induced by UUO, in WT 
and miR-33–/– mice. The contralateral kidney was used as a nonfibrotic CT. (B) qRT-PCR analysis of the expression of 
fibrosis-associated genes ASMA, FN1, and COL1A1 in WT and miR-33–/– mice in CT kidneys or following UUO surgery  
(n = 4–6). (C) Representative images and quantification of Western blot analysis of protein expression of fibrotic fac-
tors α-SMA, FN1, and COLIII in kidneys of WT and miR-33–/– mice in CT kidneys (top) or following UUO surgery (bottom). 
Relative protein levels were determined by band densitometry and are expressed in AU after correction for loading CT 
GAPDH (n = 5). (D) Quantification of levels of BUN (left) and creatinine (right) in plasma samples of WT and miR-33–/– 
mice in CT kidneys or after 3 or 10 days of UUO surgery (n = 4–6). All statistical significance was determined using 
nonparametric 2-tailed Mann-Whitney U test. Data represent the mean ± SEM and *P < 0.05 comparing miR-33–/– with 
WT mice under the same conditions.
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inflammatory cells. To this end, we performed bone marrow transplant (BMT) experiments in which lethally 
irradiated WT animals were reconstituted with bone marrow (BM) from either WT or miR-33–/– mice. One 
month after BMT, mice were injected with folic acid, and the extent of kidney fibrosis was determined after 
7 days. In contrast with our previous observations in miR-33–/– mice, kidney sections from mice reconstituted 
with miR-33–/– BM did not show any differences in the amount of Sirius red–positive staining of collagen fibers 
compared to kidneys from mice reconstituted with BM from WT mice (Figure 3B). Similarly, circulating levels 
of BUN and creatinine were not altered in mice transplanted with miR-33–/– BM (Figure 3C), nor was the induc-
tion of fibrosis-associated genes altered (Figure 3D). Although the protein levels of fibronectin were reduced in 
miR-33–/– BMT animals, other fibrotic markers, such as collagen and α-SMA, were unaffected (Figure 3E). These 
findings indicate that the impact of miR-33 on kidney fibrosis is not due to effects on BM-derived macrophages 
or other precursor hematopoietic cells and thus likely related to a localized effect within the kidney.
Figure 3. Protection from kidney fibrosis in miR-33–/– mice is not due to effects on circulating leukocytes. (A) qRT-PCR 
analysis of the expression of inflammatory genes: IL6, IL1B, TNFA, and CD68 in WT and miR-33–/– mice under CT condi-
tions or following treatment with FA (n = 6). (B) Representative microphotographs from 1 mouse per group and quantifi-
cation of Picrosirius red staining of kidneys from WT mice reconstituted with BM from WT (WT → WT) or miR-33–/– mice 
(miR-33–/– → WT) under CT conditions or following treatment with FA (n = 4); quantification is shown at the right. (C) 
Quantification of levels of BUN (left) and creatinine (right) in plasma samples of WT mice reconstituted with BM from WT 
and miR-33–/– mice under CT conditions or following treatment with FA (n = 4–6). (D) qRT-PCR analysis of the expression 
of fibrosis-associated genes ASMA, FN1, and COL1A1 in kidneys from WT mice reconstituted with BM from WT and miR-33–/– 
mice under CT conditions or following treatment with FA (n = 4–5). (E) Representative images and quantification of 
Western blot analysis of protein expression of fibrosis-associated genes: α-SMA, FN1, and COLIII in kidneys from WT mice 
reconstituted with BM from WT and miR-33–/– mice under CT conditions or following treatment with FA. Relative protein 
levels were determined by band densitometry and are expressed in AU after correction for loading CT GAPDH (n = 3). All 
statistical significance was determined using nonparametric 2-tailed Mann-Whitney U test. Data represent the mean ± 
SEM and *P < 0.05 comparing WT mice reconstituted with BM from miR-33–/– mice with animals reconstituted with WT 
BM, under the same conditions. Scale bar: 20 μm.
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Loss of  miR-33 promotes FAO and reduces lipid accumulation in fibrotic kidneys. miR-33 is an important regulator of  
FAO and cholesterol efflux. Notably, excessive lipid accumulation is known to be involved in kidney dysfunction 
(30), and impairment in FAO in renal TECs has been associated with enhanced renal fibrosis (14). Hence, we 
sought to determine whether alterations in lipid metabolism may be responsible for the protective effects of miR-
33 deficiency. Our data demonstrate that the amount of kidney triglycerides (TAGs) was significantly reduced in 
miR-33–/– mice compared with WT mice after treatment with folic acid (Figure 4A) or following UUO surgery 
(Figure 4B). We further demonstrate that FAO is enhanced in the kidneys of miR-33–/– mice, suggesting that the 
reduced lipid accumulation we observed may be due to increased FAO (Figure 4C). These effects are likely due 
at least in part to a direct action of miR-33 on CPT1a, a known target of miR-33 and critical regulator of FAO. 
Western blot analysis demonstrated that CPT1a protein levels were markedly reduced in the kidneys of mice 
Figure 4. Loss of miR-33 increases FAO and reduces renal lipid accumulation. (A and B) Quantification of triglyceride (TAG) levels in total kidney tissue 
from WT and miR-33–/– mice under CT conditions or following (A) FA treatment or (B) UUO surgery (n = 6–7). (C) Radiolabeled palmitate-derived CO2 was 
determined after incubation of 14C-palmitate with kidney tissue from WT and miR-33–/– mice (n = 5–7). (D and E) Representative images and quantification 
of Western blot analysis of protein expression of miR-33 target genes ABCA1 and CPT1A in the kidneys from WT and miR-33–/– mice under CT conditions or 
following (D) treatment with FA or (E) UUO surgery. Relative protein levels were determined by band densitometry and are expressed in AU after correction 
for loading CT GAPDH (n = 4–5). (F) Representative plots of Seahorse analysis of OCRs in primary renal TECs isolated from WT and miR-33–/– mice. Cells were 
treated with palmitate-BSA FAO substrate. Oligomycin (1 μM), FCCP (3 μM), and a combination of antimycin A (1 μM) and rotenone (1 μM) (AA/Rot) were 
injected sequentially at the indicated time points. Measurements were performed both under basal conditions and after treatment with the CPT1a inhibitor 
etomoxir (Eto). Data are represented after normalization by protein amount. Bar graphs show the values of OCR associated with maximal respiratory status 
(bottom) (n = 7–14 replicate wells; results are representative of at least 2 additional experiments with similar results). Statistical significance was deter-
mined using nonparametric 2-tailed Mann-Whitney U test (A, B, D, and E), unpaired 2-sided Student’s t test (C), and 1-way ANOVA with Bonferroni’s correc-
tion (F). Data represent the mean ± SEM and *P < 0.05 comparing tissues or cells from miR-33–/– with samples from WT mice under the same conditions.
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following folic acid treatment, and this repression was abrogated in miR-33–/– animals (Figure 4D). A similar 
protective effect on blunting the suppression of CPT1a was observed in miR-33–/– mice following UUO surgery 
(Figure 4E). To assess how miR-33 was mediating these effects, we first analyzed whether miR-33 is expressed 
in renal TECs and regulates lipid metabolism. Previous data from our laboratory (31) and miRNA tissue atlas 
database analysis (http://ccb-web.cs.uni-saarland.de/tissueatlas; Supplemental Figure 2A) show that miR-33 
is expressed in mouse and human kidneys. Furthermore, analysis of the expression of miR-33 (miR-33a-5p in 
humans) levels in 400 human primary cells (fanton.grs.riken.jp; Supplemental Figure 2B) revealed that primary 
renal TECs isolated from 2 donors expressed high levels of miR-33 (only 9 and 13 human primary cell types had 
higher miR-33 expression out of 400 tested). We further supported the expression of miR-33 by qRT-PCR (Ct = 
23) in mouse primary renal TECs (Supplemental Figure 2C). Together these data indicate that miR-33 is present 
in renal TECs. To determine how miR-33 expression influences mitochondria bioenergetics, we isolated primary 
renal TECs from WT and miR-33–/– mice and assessed the mitochondrial respiratory capacity. The results show 
that absence of miR-33 significantly enhanced the oxygen consumption rate (OCR). The effects of miR-33 defi-
ciency on OCR were diminished in cells treated with the CPT1 inhibitor etomoxir, indicating that improved FAO 
is largely responsible for these effects (Figure 4F). Overall, these data suggest that the reduced fibrosis we observed 
in miR-33–deficient animals could be related to increased FAO and reduced lipid accumulation.
miR-33 regulates FAO in human renal TECs. We next sought to determine whether alterations in miR-33 
expression could contribute to the development of  kidney dysfunction in human cells. Using the HKC-8 
Figure 5. miR-33 regulates FAO in human kidney tubule cells. (A) Representative plots of Seahorse analysis of OCRs in the human tubular cell line HKC-8 
transfected with CT or miR-33 mimics (left). Cells were treated with palmitate-BSA FAO substrate. Measurements were performed both under basal 
conditions and after treatment with the CPT1a inhibitor Eto to calculate the magnitude of several phases and parameters of mitochondrial respiration. Bar 
graphs show the OCRs associated with maximal respiratory status (right) (n = 9 replicate wells). (B) qRT-PCR analysis of the expression of miR-33 target 
genes involved in FAO, CPT1a, CROT, and HADHB, in HKC-8 cells transfected with CT or miR-33 mimics (n = 3). (C) Representative plots of Seahorse analy-
sis of OCRs in HKC-8 cells transfected with CT or miR-33 inhibitors (left). Measurements were performed both under basal conditions and after treatment 
with Eto to calculate the magnitude of several phases and parameters of mitochondrial respiration. Bar graphs show the OCRs associated with maximal 
respiratory status (right) (n = 9 replicate wells). (D) qRT-PCR analysis of the expression of miR-33 target genes involved in FAO, CPT1a, CROT, and HADHB, 
in HKC-8 cells transfected with CT or miR-33 inhibitors (n = 3). Statistical significance was determined using 1-way ANOVA with Bonferroni’s correction (A 
and C) and nonparametric 2-tailed Mann-Whitney U test (B and D). All data represent the mean ± SEM and *P < 0.05 comparing HKC-8 cells transfected 
with miR-33 mimics/inhibitors with cells transfected with CT constructs under the same conditions.
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human renal TEC line, we observed that the expression of  miR-33 was not affected by treatment with 
the profibrotic cytokine TGF-β (Supplemental Figure 3). We further demonstrate that treatment with 
miR-33 mimics is sufficient to reduce mitochondrial respiration in human kidney cells and that these 
effects are largely abolished by inhibition of  FAO (etomoxir) (Figure 5A). Consistent with this, mRNA 
expression levels of  CPT1a and other miR-33 targets involved in FAO (CROT, HADHB) were reduced in 
cells treated with miR-33 mimics (Figure 5B). Alternatively, treatment of  HKC-8 cells with an inhibitor 
of  miR-33 improved mitochondrial respiration (Figure 5C) and increased mRNA expression of  miR-33 
targets involved in FAO (Figure 5D).
Treatment with miR-33 inhibitors targeted to the kidney. We next assessed whether inhibition of  miR-33 
could be an effective therapeutic strategy to prevent folic acid–induced kidney damage. miR-33 inhib-
itors have previously been used as a strategy for raising circulating HDL-cholesterol and reducing ath-
erosclerotic plaque size in animal models (32). However, long-term treatment with miR-33 inhibitors or 
genetic loss of  miR-33 has been shown to result in detrimental unintended effects (33–35). As such, new 
strategies to deliver inhibitors to atherosclerotic plaques or disrupt binding of  specific miR-33 targets 
could provide a more effective strategy. With this in mind, we have used the recently developed pHLIP, 
Figure 6. pH low inducible peptides promote delivery of miR-33 inhibitors to the kidney. (A) Generation of anti–miR-33 PNA-conjugated pH low insertion 
peptides (pHLIP) capable of delivering miR-33 inhibitors to acidic microenvironments. (B) Representative images of tissues from 1 mouse per group 
injected with fluorescently labeled noninserting CT (pHLIP-750-5K) or targeted (pHLIP-750) constructs. (C) Representative images demonstrating uptake 
of fluorescently labeled pHLIP constructs (pHLIP-A546) into primary renal TECs in vitro (shown in red). Costaining with lotus tetragonolobus lectin (LTL), 
a marker for proximal tubules is shown in green. (D) Representative flow cytometry histograms showing fluorescence intensities in primary renal tubular 
cells treated with CT (pHLIP-A546-5K), or targeted (pHLIP-A546) constructs. (E) Representative images and quantification of Western blot analysis of 
protein expression of miR-33 targets CPT1A and CROT in the kidneys of mice treated with pHLIP scrambled CT (ScrpHLIP) or miR-33 inhibitory RNA con-
structs (anti–miR-33pHLIP) under CT conditions (top) or following treatment with FA (n = 10–11). Statistical significance was determined using nonparametric 
2-tailed Mann-Whitney U test. All data represent the mean ± SEM and *P < 0.05 comparing mice treated with anti–miR-33pHLIP with animals treated with 
ScrpHLIP under the same conditions. Scale bar: 20 μm.
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which can deliver miRNA inhibitors, or other small oligonucleotides, selectively to areas of  high acidi-
ty. This strategy has previously been employed to deliver miRNA inhibitors to the acidic microenviron-
ment of  tumors (36). The capacity of  some portions of  the mammalian nephron to secrete hydrogen 
ions (37) theoretically provides an acidic microenvironment. This, together with the fact that original 
reports have documented pHLIP renal accumulation (38), led us to develop anti–miR-33pHLIP PNA 
constructs to inhibit miR-33 in the kidney (Figure 6A). Assessment of  fluorescently labeled constructs 
(TAMRA dye) confirmed that whereas standard delivery systems and noninserting control constructs 
(pHLIP-750-K) convey inhibitors primarily to the liver, functional pHLIP constructs (pHLIP-750) have 
extremely high uptake in the kidney (Figure 6B). Furthermore, we demonstrate uptake of  fluorescent 
pHLIP constructs in primary renal tubular cells by both fluorescent microscopy (Figure 6C) and flow 
cytometry (Figure 6D and Supplemental Figure 4). Notably, we demonstrate that treatment with anti–
miR-33pHLIP constructs significantly increases protein levels of  CPT1a as well as CROT, another miR-33 
Figure 7. Selective delivery of miR-33 inhibitors abrogated FA-induced renal fibrosis. (A) qRT-PCR analysis of the expression of fibrotic genes ASMA, FN1, 
and COL1A1 in the kidneys of mice treated with ScrpHLIP or anti–miR-33pHLIP under CT conditions or following treatment with FA (n = 5). (B) qRT-PCR analysis 
of the expression of inflammatory genes IL6, IL1B, TNFA, and COL1A1 in the kidneys of mice treated with ScrpHLIP or anti–miR-33pHLIP under CT conditions 
or following treatment with FA (n = 6–7). (C) Representative images and quantification of Western blot analysis of protein expression of fibrosis-associ-
ated genes: α-SMA, FN1, and COLIII in the kidneys of mice treated with ScrpHLIP or anti–miR-33pHLIP under CT conditions or following treatment with FA (n = 
10–11). (D) Representative microphotographs from mice treated with ScrpHLIP or anti–miR-33pHLIP after treatment with FA. (E) Quantification of levels of BUN 
(left) and creatinine (right) in plasma samples of mice treated with ScrpHLIP or anti–miR-33pHLIP constructs under CT conditions or following treatment with 
FA (n = 10–11). Statistical significance was determined using nonparametric 2-tailed Mann-Whitney U test. All data represent the mean ± SEM and *P < 
0.05 comparing mice treated with anti–miR-33pHLIP with animals treated with ScrpHLIP under the same conditions. Scale bar: 100 μm.
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target involved in FAO (Figure 6E). However, the expression of  other known targets of  miR-33 that 
are involved in FAO and mitochondrial function, including PGC-1α and AMPK, were not found to be 
altered in the kidneys of  these mice (Supplemental Figure 5).
Importantly, we found that treatment with anti–miR-33pHLIP PNA constructs can substantially reduce 
folic acid–induced kidney fibrosis. Similar to what we observed in miR-33–/– animals, treatment with anti–
miR-33pHLIP constructs reduced the induction of  genes involved in both fibrosis (Figure 7A) and inflammation 
(Figure 7B) in the kidney following folic acid treatment compared with scramble control PNAs (ScrpHLIP). 
Similarly, the expression of  proteins involved in fibrosis was significantly reduced in animals treated with 
anti–miR-33pHLIP constructs (Figure 7C). We also performed histological staining of  kidney sections from 
these animals (Figure 7D) and assessed circulating factors associated with renal function, demonstrating a 
significant decrease in circulating BUN and a similar trend for creatinine (Figure 7E).
Discussion
Although there are many causes of  kidney dysfunction, alterations in metabolic function play an important 
role in both the development and progression of  CKD, including DN and tubulo-interstitial fibrosis, the 
latter being the final common pathway for hypertensive renal disease and nephrosclerosis. Indeed, one of  
the most common conditions in patients with diabetes mellitus is DN, which in turn is one of  the largest 
contributors to ESRD. In addition to ESRD, patients with DN are also much more likely to suffer from 
events associated with cardiovascular disease (CVD) (39). Although very distinct, CKD and CVD are both 
chronic inflammatory conditions associated with altered lipid metabolism (40). miR-33 is a well-known 
mediator of  lipid metabolism and a promising target for the treatment of  CVD (41). In this work, we show 
that loss of  miR-33 protects against the development of  kidney fibrosis, demonstrating the potential for 
anti–miR-33 therapeutics that can target both CKD and CVD in patients suffering ESRD.
By using 2 models of  renal injury (folic acid and UUO), we show that the genetic ablation of  
miR-33 protects from the development of  renal fibrosis. In addition, the presence of  proinflammatory 
markers typical of  early fibrogenesis was also reduced. Inflammation contributes significantly to fibro-
genesis (42), and miR-33 has been reported to influence macrophage polarization and shown to play an 
important role in the development of  other chronic inflammatory conditions, such as atherosclerosis. 
Additional evidence suggests that miR-33 facilitates renal fibrosis in DN through the activation of  the 
NF-κB/TGF-β inflammation pathway (28). However, our data from BMT experiments demonstrate 
that the protection from kidney fibrosis observed in miR-33–/– mice was not due to differences in circu-
lating leukocytes, but rather to the local effect of  miR-33 on TECs and other cells within the kidney. 
Because our work focuses on the metabolic facet of  renal fibrosis and the action of  miR-33 in TECs, we 
have not explored in depth the role of  resident macrophages, which are important contributors to renal 
fibrogenesis and would unlikely be replaced following BMT (43, 44). Also, this work has not addressed 
whether miR-33 impinges on other pathogenic pathways related to CKD and fibrogenesis, such as epi-
thelial-mesenchymal transition (45, 46).
Excessive lipid accumulation and impaired FAO have been repeatedly observed in several animal models 
of  acute and chronic renal injury, as well as in human patients (10, 11, 13, 47, 48). Increased lipid accumu-
lation induces cellular lipotoxicity, contributing to fibrosis development (11). Although cell-specific overex-
pression of  CD36 in TECs from mice leads to lipid accumulation, it is not sufficient to drive spontaneous 
renal fibrogenesis (49). Therefore, it appears that defects in energy production have detrimental consequences 
beyond mere lipid accumulation. miR-33 may also promote the accumulation of  lipid droplets in the kidney 
as described in other organs, thus contributing to kidney damage (33). The importance of  impaired mito-
chondrial respiration as a forerunner of  tubular damage is also underscored by the fact that mitochon-
drial substrate overload surpasses the catabolic capacity of  mitochondrial β-oxidation and promotes tubular 
injury (12, 50). A decrease in the expression of  key metabolic transcription factors (PPARGC1A, PPARA, and 
PPARG) in tubule cells (15) has been associated with the progression of  fibrosis and CKD. Transgenic expres-
sion of  PPARGC1A and PPARA caused protection from acute kidney injury or kidney fibrosis, indicating the 
key role of  metabolic pathways in maintaining kidney function and tubule health (10, 13, 51, 52). Further-
more, age-associated impairment of  PPARα and FAO aggravates renal fibrosis (53). Consistent with this, the 
pharmacological activation of  PPARα by its agonist fenofibrate not only improved FAO but also significantly 
reduced renal fibrosis development in the UUO and folic acid models. In addition, treatment with C75, a 
synthetic compound that increases CPT1 activity and blocks fatty acid synthase, attenuated kidney fibrosis 
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associated with FA administration (11). This molecule was also protective in the ischemia/reperfusion inju-
ry model, where stimulation of  CPT1 activity by C75 recovered ATP depletion, improved renal function, 
attenuated tissue injury, and inhibited proinflammatory cytokine production and neutrophil infiltration (54). 
Nevertheless, neither fibrates nor C75 are currently accepted therapies for CKD either because of  side effects 
on renal function or lack of  pharmaceutical development. As such, novel treatments aimed at preventing 
CKD-associated metabolic alterations could provide a promising approach for the treatment of  CKD.
miR-33 has been demonstrated to be a key regulator of  FAO because of  its ability to regulate key 
enzymes in this process, including CPT1a. TECs rely exclusively on FAO and are unable to switch to 
glycolysis in response to energy demand. Thus, pharmacological inhibition of  CPT1 results in ATP 
depletion, cell death, and dedifferentiation (11). In line with these observations, we observed that 
FAO-associated mitochondrial respiration is increased in renal TECs from miR-33–/– animals. These 
effects were greatly diminished in cells treated with etomoxir, indicating that these changes are large-
ly due to the action of  miR-33 on FAO. Other miR-33 targets involved in regulating mitochondrial 
function and glucose metabolism could also contribute to the improved respiratory capacity of  TECs 
from miR-33–/– animals and the trend toward increased respiration even after inhibition of  CPT1a. The 
improved FAO in these cells was reflected in an increased capacity of  kidney tissue from miR-33–/– mice 
to oxidize 14C-palmitate. Consistent with this, the expression of  CPT1a was increased in these mice 
following renal injury, and the accumulation of  lipids in the kidneys of  these animals was dramatically 
reduced. Furthermore, our results in human kidney cells are also strongly supportive of  a potential role 
for miR-33 in human kidney fibrosis. Studies of  mitochondrial respiration and ATP production in these 
cells demonstrated similar effects on FAO, exemplified by the changes in the expression of  CPT1a, as 
well as other miR-33 targets involved in FAO (CROT and HADHB). These findings suggest that treat-
ment of  human patients with inhibitors of  miR-33 could increase the expression of  genes involved in 
FAO and reduce lipid accumulation, which could help protect against kidney dysfunction.
miRNAs have emerged as powerful regulators of  fibrotic processes in the kidney (55, 56). Thus, Gomez 
et al. identified 24 miRNAs that were commonly upregulated both in human CKD and in animal models 
of  kidney injury, suggesting a “fibrotic” miRNA signature in the kidney (18). miR-21 is arguably the first 
miRNA shown to promote fibrosis by targeting PPARα-related metabolic pathways (22). Anti–miRNA-21 
oligonucleotide-based therapy has also confirmed this finding in the murine model of  Alport nephropathy 
by reversing the associated mitochondrial dysfunction (17). Although the mechanism of  action of  miR-
214 in fibrosis is less well elucidated, it appears that miR-214 also targets metabolic responses (18). Earlier 
work has suggested that miR-33 may play a role in the regulation of  hepatic fibrosis, as it was reported that 
inhibition of  miR-33 reduces the mRNA expression of  some fibrosis-associated factors in a nonalcoholic 
steatohepatitis model (57). A profibrotic role for miR-33 has been also reported in cardiac fibrosis, as car-
diac fibroblast-specific deficiency of  miR-33 reduced cardiac fibrosis in response to pressure overload by 
transverse aortic constriction. The proposed mechanism underlying this response was that deficiency of  
miR-33 impaired cardiac fibroblast proliferation because of  altered lipid raft cholesterol content (58, 59). 
In the kidney, we demonstrate an important role for miR-33 in the regulation of  FAO in TECs, which may 
be relevant to explain its effects on fibrogenesis. However, it is likely that other known or predicted miR-33 
targets may also be involved in helping promote these actions.
Because of  their important role in the regulation of  metabolic function and other pathways related to 
fibrosis, miR-33 and other miRNAs could provide useful therapeutic targets for kidney disease. However, 
the promiscuous nature of  miRNAs increases the potential for unintended consequences, as has previous-
ly been observed with long-term treatment with inhibitors of  miR-33 (33). Therefore, the ability to target 
miRNA mimics and inhibitors to specific tissues could greatly enhance their therapeutic potential. In this 
work, we used pHLIP technology to selectively deliver miR-33 inhibitors to the kidney, based on their 
affinity for acidic microenvironments (36). We observed efficient uptake into the kidney and demonstrated 
that selective delivery of  miR-33 inhibitors to the kidney is sufficient to reduce folic acid–induced kidney 
damage. These findings highlight the therapeutic potential of  anti–miR-33pHLIP constructs for the treat-
ment of  CKD, while minimizing the potential risks of  detrimental effects in other organs. Conceivably, a 
similar approach can be used to selectively target other profibrotic miRNAs or deliver protective miRNAs 
into the kidney. Hence, these findings highlight the potential for the selective targeting of  kidney miRNAs 
as a therapy for patients with CKD.
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Methods
Animals, BM transplantation, and models of renal fibrosis
Male C57BL/6 (WT) mice were originally purchased from The Jackson Laboratory (Bar Harbor, Maine, 
USA) and kept under constant temperature and humidity in a controlled 12-hour light/12-hour dark 
cycle. miR-33–/– mice were generated and characterized, and BMTs were performed as we have previously 
described (35). Briefly, 8-week-old male mice were lethally irradiated twice 4 hours apart with a total dose 
of  5.5 Gy (550 rads) before transplantation (X-RAD320, Precision X-Ray Inc.). BM was collected from 
femurs of  WT or miR-33–/– mice by flushing with sterile OptiMEM. Each recipient mouse was reconsti-
tuted with 2 × 106 BM cells through retroorbital injection. Four weeks after BMT, peripheral blood was 
collected by retroorbital venous plexus puncture for PCR analysis of  BM reconstitution.
Mouse models of kidney fibrosis
UUO. UUO surgery procedure was performed as previously described (60). Briefly, mice were anesthe-
tized with isoflurane (3%–5% for induction and 1%–3% for maintenance). Mice were shaved on the left 
side of  the abdomen, a vertical incision was made through the skin with a scalpel, and the skin was 
retracted. A second incision was made through the peritoneum to expose the kidney. The left ureter was 
ligated twice 15 mm below the renal pelvis with surgical silk, and the ureter was then severed between 
the 2 ligatures. Then, the ligated kidney was placed gently back into its correct anatomical position, and 
sterile saline was added to replenish loss of  fluid. The incisions were sutured and mice were individually 
caged. Buprenorphine was used as an analgesic. A first dose was administered 30 minutes before surgery 
and then every 12 hours for 72 hours, at a dose of  0.05 mg/kg subcutaneously. Mice were sacrificed by 
CO2 overdose, and kidney and blood samples were harvested after perfusion with PBS at 3 and 10 days 
after UUO. Contralateral kidneys were used as a nonfibrotic control for all experiments using this model.
FAN. In this model kidney fibrosis was induced by i.p. injection with 250 mg folic acid per kilogram 
body weight dissolved in 0.3 M sodium bicarbonate (vehicle) as previously described (61). Control animals 
received 0.3 mL of  vehicle (i.p.). Mice were sacrificed by CO2 overdose, and kidneys and blood samples 
were harvested after perfusion with PBS after 7 days of  FA administration.
Histology, immunohistochemistry, and morphometric analyses
Kidneys were fixed in 10% neutral buffered formalin overnight, bisected sagittally, and submitted for standard 
paraffin processing before sectioning at 5 μm. Sections were stained with H&E, or Sirius red, to evaluate extent 
of renal injury and associated fibrosis. To quantify fibrosis, 20 randomly selected fields across 4 sections, evenly 
distributed from pole to pole, limited to the cortex and avoiding preexisting perivascular and capsular collagen, 
were captured with a ×20 objective using a polarizing filter and Leica DFC 495 digital camera connected to 
a light microscope (Zeiss Axioskop). The area occupied by collagen was measured in each field using a com-
puterized image analysis system (Leica Application Suite X, Leica Microsystems Inc.) and expressed in square 
micrometers. The pathologist was blinded to genotype and treatment status of individual animals.
Cell culture
Human proximal TECs (HKC-8) were cultured in DMEM/F12 (1:1 vol/vol) supplemented with 15 mM 
HEPES, 5% (vol/vol) fetal bovine serum, 1× insulin-transferrin-selenium, 0.5 μg/mL hydrocortisone, 50 
U/mL penicillin, and 50 μg/mL streptomycin at 37°C and 5% CO2. HKC-8 cells were provided by Katalin 
Susztak (Department of  Medicine, Perelman School of  Medicine, University of  Pennsylvania, Philadel-
phia, Pennsylvania, USA). HKC-8 cells were transfected with 40 nM miR-33 mimic or 60 nM miR-33 
inhibitor using RNAiMAX (Thermo Fisher Scientific) for 8 hours, as described previously (62). All experi-
mental control samples were treated with an equal concentration of  a nontargeting control mimic sequence 
or an inhibitor negative control sequence. Between 48 and 72 hours after transfection, cells were collected 
for bioenergetic or mRNA analysis.
Isolation of primary kidney TECs
Kidneys from miR-33–/– and WT mice were collected after sacrifice and subjected to PBS perfusion (10 
mL) followed by collagenase type II digestion (2 mg/mL, 10 mL). After digestion, the renal capsule and 
medulla was removed. The rest of  the kidney was minced and further digested in collagenase buffer for 
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an additional 5 minutes at 37°C with rotation to release cells. Digested tissue and cell suspension were 
passed through a 70-μm cell strainer, centrifuged at 50 g for 5 minutes, and washed in PBS for 2 rounds to 
collect TECs. Isolated TECs were seeded onto a collagen-coated Petri dish and cultured in renal epithelial 
cell medium (C-26130, PromoCell) supplemented with growth factors, including insulin, epinephrine, and 
epidermal growth factor for TEC growth, as well as hydrocortisone for limiting growth of  potential con-
taminating macrophages derived from the isolation (63).
Cellular bioenergetic analysis
FAO-associated OCR was studied using high-throughput extracellular flux analysis (Seahorse XFe96 and XFe24 
analyzers, Agilent Technologies). Ex vivo, primary TECs isolated from WT or miR-33–/– mice were seeded onto 
collagen-coated XFe96 cell culture microplates 24 hours before extracellular flux analysis. Growth medium was 
replaced with substrate-limited medium (DMEM supplemented with 0.5 mM glucose and 1 mM glutamate) 
the night before Seahorse assay. On the assay day, substrate-limited medium was replaced with Krebs-Henseleit 
buffer assay medium supplemented with 0.2% carnitine for 1 hour at 37°C without CO2. The CPT1 inhibitor 
etomoxir (MilliporeSigma) was added (4 μM) to the corresponding wells 15 minutes before starting the assay. 
Finally, just before starting the assay, BSA or 200 mM palmitate-BSA FAO substrate was added.
Immediately, XF Cell Mito Stress Test was performed in a Seahorse XFe96 analyzer. FAO was assayed 
through measurement of  OCR changes in response to sequential injections of  4 compounds: oligomycin (1 
μM, port A), FCCP (1 μM, port B), and antimycin/rotenone (1 μM, port C). After Seahorse assay, Hoechst 
staining was performed for data normalization.
In vitro, 2 × 104 HKC-8 cells were transfected with miR-33 mimics, miR-33 inhibitors, or correspond-
ing negative control sequences. Cells were then seeded in a Seahorse Bioscience XFe24 cell culture micro-
plate, followed by the abovementioned preparation steps, and given 400 μM etomoxir treatment before 
OCR measurements in response to oligomycin (1 μM, port A), FCCP (3 μM, port B), and antimycin/
rotenone (1 μM, port C) in an XFe24 analyzer. After the assay, protein was extracted from wells with 0.1% 
NP-40–PBS solution and quantified with bicinchoninic acid protein assay (Thermo Fisher Scientific) for 
data normalization. OCR and maximal respiration were determined as described previously (63, 64).
Kidney TAG measurement
Renal tissue lipids were sequentially extracted by the method of  Bligh and Dyer (65) in the presence of  
internal standards, including di-eicosanoyl–PC, di-tetradecanoyl–PE, and cholesteryl heptadecanoate. 
Extracted renal lipids were resuspended in methanol/chloroform (4:1, by vol) to a dilution of  about 20 
pmol of  lipid per microliter and analyzed by electrospray ionization mass spectrometry in the direct infu-
sion mode at a flow rate of  3 μL/min using a Thermo Fisher Scientific Electron TSQ Quantum Ultra 
instrument.
FAO
FAO was assayed as previously described (66). In brief, kidneys were removed from WT and miR-33–/– mice 
and homogenized in 5 volumes of  chilled STE buffer (pH 7.4, 0.25 M sucrose, 10 mM Tris-HCl, and 1 
mM EDTA). The homogenate was immediately centrifuged and the pellet was resuspended and incubated 
with a reaction mixture containing 0.5 mmol/L palmitate (conjugated to 7% BSA/[14C] palmitate at 0.4 
μCi/mL) for 30 minutes. After this incubation period, the resuspended pellet-containing reaction mixture 
was transferred to an Eppendorf  tube, the cap of  which housed a Whatman filter paper disc that had been 
presoaked with 1 mol/L sodium hydroxide. The 14CO2 trapped in the reaction mixture medium was then 
released by acidification of  medium using 1 mol/L perchloric acid and gentle agitation of  the tubes at 
37°C for 1 hour. Radioactivity that had become adsorbed onto the filter disc was then quantified by liquid 
scintillation counting in a beta counter.
Creatinine and BUN measurements
Briefly, creatinine was extracted from 20 μL of  serum via a protein precipitation crash out using acetoni-
trile. The resulting extraction was then spiked with internal deuterated creatinine and analyzed via Ultra 
High Pressure Liquid Chromatography System (Agilent Technologies) coupled in-line to a 4000 Q-Trap 
mass spectrometer (AB Sciex). The extract was injected onto an Agilent Technologies column coupled to 
an analytical Phenomenex SecurityGuard trap (C18, 4 × 3.0 mm). The column and trap were kept at 40°C. 
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Bound creatinine was eluted at a flow rate of  500 μL/min using an acetonitrile/water mobile phase mixture 
containing 0.1% formic acid. First quartile to (m/z 114) third quartile (m/z 44) and first quartile (m/z 117) to 
third quartile (m/z 47) transitions were monitored for H3-creatinine (serum sample) and D3-creatinine (refer-
ence internal standard) abundance, respectively. Mass spectral data were collected and analyzed/quantified 
using Analyst software (v.1.5). Standard curves of  D3-creatinine were used to ensure linearity within the 
creatinine measurements in the serum samples. Quantitative colorimetric determination of  urea nitrogen in 
plasma was performed using the diacetylmonoxime (DAM) method and measured at 520 nm on the Excel 
Chemistry Analyzer (Stanbio Laboratory, Boerne, Texas, USA).
Western blot analysis
Kidneys were homogenized by manual disruption and the Bullet Blender Homogenizer and lysed in ice-
cold buffer containing 50 mM Tris-HCl at pH 7.5, 0.1% SDS, 0.1% deoxycholic acid, 0.1 mM EDTA, 
0.1 mM EGTA, 1% NP-40, 5.3 mM NaF, 1.5 mM NaP, 1 mM orthovanadate, and 1 mg/mL protease 
inhibitor cocktail (Roche) and 0.25 mg/mL AEBSF (Roche). Lysates were sonicated and rotated at 4°C 
for 1 hour before the insoluble material was removed by centrifugation at 12,000 g for 10 minutes. After 
normalizing for equal protein concentration, cell lysates were resuspended in SDS sample buffer before 
separation by SDS-PAGE. Following transfer of  the proteins onto nitrocellulose membranes, the mem-
branes were probed with the following antibodies: ABCA1 (Abcam; ab18180; 1:1000), CROT (Novus; 
3144; 1:1000), CPT1a (Abnova; H00001374-DO1P; 1:1000), GAPDH (AF5718; 1:2000), α-SMA (Milli-
poreSigma; A5228; 1:2000), FN1 (MilliporeSigma; F3648; 1:1000), COLIII (Abcam; ab7778; 1:1000), and 
VINCULIN (MilliporeSigma; V9131; 1:2000). Protein bands were visualized using the Odyssey Infrared 
Imaging System (LI-COR Biotechnology), and densitometry was performed using ImageJ software (NIH).
RNA isolation and qRT-PCR
Total RNA from cells and tissue was isolated using TRIzol reagent (Invitrogen, Thermo Fisher Scien-
tific) according to the manufacturer’s protocol. For mRNA expression analysis, cDNA was synthesized 
using iScript RT Supermix (Bio-Rad), following the manufacturer’s protocol. qRT-PCR analysis was 
performed in duplicate using SsoFast EvaGreen Supermix (Bio-Rad) on an iCycler Real-Time Detec-
tion System (Eppendorf). The mRNA levels were normalized to 18S. Quantitative PCR primers are 
listed in Supplemental Table 1.
PNA synthesis and pHLIP-PNA conjugate synthesis
pHLIP-PNA conjugations were performed as previously described (38). First, pHLIP-Cys (ADDQNP-
WRAYLDLLFPTDTLLLDLLWCG, CS Bio) was conjugated with Aldrithiol-2 (MilliporeSigma) to get 
pHLIP-Cys(Pys). Aldrithiol-2 was added to peptide in dimethylformamide (DMF) to have a molar ratio of 1:1. 
One hundred millimoles sodium phosphate and 150 mM NaCl buffer, pH 7.2 (saturated with argon), was add-
ed to the reaction mix (one-twentieth of total volume). Reaction mixture was incubated at room temperature 
for 1 hour. pHLIP-Cys(Pys) was purified by reverse-phase HPLC (Zorbax SB-C18 columns, 9.4 × 250 mm, 5 
μm; Agilent Technologies, the gradient consisting of a binary solvent system using water and acetonitrile with 
0.05% trifluoroacetic acid [TFA] for 20%–70% over 40 minutes), lyophilized, and characterized by surface-en-
hanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry. Second, PNAs were added 
to pHLIP-Cys(Pys) in DMSO (molar ratio 1:3) in the presence of 0.1 M ammonium bicarbonate, pH 8.8 (satu-
rated with argon), one-fifth of total volume, and the reaction mixture was incubated overnight at 30°C. pHLIP-
PNA was purified by reverse-phase HPLC (Zorbax SB-C18 columns, 9.4 × 250 mm, 5 μm; Agilent Technolo-
gies, the gradient consisting of a binary solvent system using water and acetonitrile with 0.05% TFA for 5%–65% 
over 40 minutes), lyophilized, and characterized by SELDI-TOF mass spectrometry.
pHLIP and K-pHLIP conjugation with Alexa Fluor 750 and Alexa Fluor 546 fluorescent dye
pHLIP (ACDDQNPWRAYLDLLFPTDTLLLDLLWA) and K-pHLIP (ACKKQNPWRAYLKLLFPTK-
TLLL KLLW) were conjugated at the N-terminus with Alexa Fluor 546– and Alexa Fluor 750–maleimide 
(Life Technologies) in DMF at a ratio of  1:1 at room temperature for about 2 hours. One hundred millimoles 
sodium phosphate and 150 mM NaCl buffer, pH 7.2 (saturated with argon), was added to the reaction mix 
(one-twentieth of  total volume). The reaction progress was monitored by the analytical reverse-phase HPLC 
(Zorbax SB-C18 column, 4.6 × 250 mm, 5 μm; Agilent Technologies; the gradient consisting of  a binary 
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solvent system using water and acetonitrile with 0.05% TFA for 20%–75% over 30 minutes). More Alexa 
Fluor–maleimide was added to the reaction mix, if  it was needed. Constructs were purified by reverse-phase 
HPLC (Zorbax SB-C18 columns, 9.4 × 250 mm, 5 μm; Agilent Technologies, the same gradient, over 40 
minutes), lyophilized, and characterized by SELDI-TOF mass spectrometry. The concentrations of  the con-
structs were determined by their absorbance using the following molar extinction coefficients: ε554 = 93,000 
M/cm (for Alexa Fluor 546–pHLIPs), and ε753 = 290,000 M/cm (for Alexa Fluor 750–pHLIPs).
Assessment of pHLIP delivery
To determine the specificity of  pHLIP delivery, animals were injected intravenously with pHLIP-750 or the 
noninserting control peptide pHLIP-750-5K (4 nmol). Animals were sacrificed after 12 hours and uptake 
was determined in different tissues by near-infrared fluorescence imaging, performed on an IVIS Spectrum 
system (Caliper Life Science) with appropriate excitation (Ex) and emission (Em) filter sets (Ex/Em = 
745/800 nm). Additionally, kidney sections were blocked with 10% donkey serum for 30 minutes and 
stained with LTL (FL1321, Vector Laboratories) for 30 minutes at room temperature for localization of  
renal epithelial cells (67). For flow cytometry analysis, kidneys were harvested 4 hours after injection with 
pHLIP-546-5K or pHLIP-546, and cell dissociation was performed as described for isolation of  kidney epi-
thelial cells. A mixture of  kidney cells was passed through a 70-μm cell strainer, and kidney epithelial cells 
were stained with LTL (FL1321, Vector Laboratories). Flow cytometry was performed using a BD LSRII 
(BD Biosciences), and data were analyzed using FlowJo software v8.7 (Tree Star, Inc.).
Anti–miR-33pHLIP treatment
ScrpHLIP and anti–miR-33pHLIP constructs were administered by intravenous injection at a dose of  1 mg/kg 
body weight in PBS with 5% DMSO. Injections were performed 2 days before, the day of, 2 days after, and 
5 days after administration of  folic acid.
Statistics
Animal sample size for each study was chosen based on literature documentation of  similar well-character-
ized experiments. The number of  animals used in each study is listed in the figure legends. In vitro exper-
iments were routinely repeated at least 3 times unless otherwise noted. No inclusion or exclusion criteria 
were used. Data are expressed as average ± SEM. Statistical differences were measured using an unpaired 
2-sided Student’s t test or 1-way ANOVA with Bonferroni’s correction for multiple comparisons. Normality 
was checked using the Kolmogorov-Smirnov test. A nonparametric test (Mann-Whitney) was used when 
data did not pass the normality test. P ≤ 0.05 was considered statistically significant. Data analysis was 
performed using GraphPad Prism software version 7.
Study approval
All the experiments were approved by the Institutional Animal Care Use Committee of  Yale University 
School of  Medicine.
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